@Article{biocell.2021.010261,
AUTHOR = {ZHIXIONG WANG, NA RISU, JIAYU FU, HUI LIU, GUOMIN ZHOU, QIAN LIU, YAN ZOU, JIAXING TANG, LONG LI, XUEKAI ZHU},
TITLE = {Pomalidomide improves the function of CD133- or HER2-specific CAR T cells},
JOURNAL = {BIOCELL},
VOLUME = {45},
YEAR = {2021},
NUMBER = {1},
PAGES = {157--165},
URL = {http://www.techscience.com/biocell/v45n1/41409},
ISSN = {1667-5746},
ABSTRACT = {Chimeric antigen receptor (CAR) T-cell therapy is mostly limited to hematological malignancies and has a poor
effect on solid tumors. CAR T cells as a kind of immune cell may be affected by some immunomodulatory drugs such as
pomalidomide, so the use of pomalidomide may improve the effect of CAR T cells on solid tumors. In this study, CD133-
or HER2-specific CAR T cells were chosen to investigate whether pomalidomide can regulate the function of CAR T cells
<i>in vitro</i>. We found that pomalidomide can significantly enhance the ability of CD133-CAR T cells and HER2-CAR T cells
to kill tumor cells and increase the cytokine secretion of CD133-CAR T cells and HER2-CAR T cells. Also, pomalidomide
was shown to induce down-regulation of protein levels of IL-2 transcriptional repressors Aiolos and Ikaros in CAR T cells.
This study suggests that the combination of pomalidomide and CAR T cells may be a new strategy for the treatment of
solid tumors.},
DOI = {10.32604/biocell.2021.010261}
}